Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17328038 | 1.00 | SIGMAR1 (0.44) | SIGMAR1CHRM3CHRM5HSD17B10PLA2G10 | |
| SCHEMBL4213475 | 1.00 | SIGMAR1 (0.44) | SIGMAR1CHRM3CHRM5HSD17B10PLA2G10 | |
| Bromide SCHEMBL22800758 | 0.98 | SIGMAR1 (0.43) | SIGMAR1CHRM3CHRM5HSD17B10PLA2G10 | |
| SCHEMBL7044717 | 0.98 | SIGMAR1 (0.43) | SIGMAR1CHRM3CHRM5HSD17B10PLA2G10 | |
| SCHEMBL583320 | 0.94 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL1149470 | 0.94 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Bromide SCHEMBL583318 | 0.92 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL8209880 | 0.92 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL4771744 | 0.92 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL649131 | 0.92 | SIGMAR1 (0.50) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010084090-A1 | PYRIDYL-AZA(THIO)XANTHONE SENSITIZER COMPRISING LANTHANIDE(III) ION COMPLEXING COMPOUNDS, THEIR LUMINESCENT LANTHANIDE (III) ION COMPLEXES AND USE THEREOF AS FLUORESCENT LABELS. | CIS BIO INTERNATIONAL (FR) | 2010-07-29 | — | — | WO | disclosed |
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1140203-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7138104-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-7052673-B2 | Pharmaceuticals for the imaging of angiogenic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-7018611-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | LANTHEUS MEDICAL IMAGING, INC. | 2006-01-05 | — | — | US | disclosed |
| US-6524553-B2 | A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a qinolone nonpeptide, and binds to a receptor that is upregulated during angiogenesis | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6511649-B1 | Chemotherapeutic, a radiosensitizer agent, and a targeting moiety bound to chelator and is a quinolone nonpeptide that binds to a receptor; therapeutically effective radioisotope or diagnostically effective imageable moiety; cancer | LANTHEUS MI REAL ESTATE, LLC | 2003-01-28 | — | — | US | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | CARPENTER ALAN P (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-03 | — | — | US | disclosed |
| US-6322770-B1 | FOR DIAGNOSIS AND TREATMENT OF CANCER, IMAGING TUMORS, MONITORING THERAPEUTIC ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; COMPRISED OF TARGETING MOIETY THAT BINDS TO RECEPTOR AND RADIOISOTOPE | DUPONT PHARMACEUTICALS COMPANY | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | SIGMAR1 398/4885CHRM3 942/4885CHRM5 604/4885 |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | SIGMAR1 2007/4885CHRM3 937/4885CHRM5 687/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | SIGMAR1 648/4885CHRM3 999/4885CHRM5 638/4885 |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | VEGFA, FLT4, FLT1 | SIGMAR1 832/4885CHRM3 2910/4885CHRM5 2720/4885 |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | FLT4, VEGFA, FLT1 | SIGMAR1 667/4885CHRM3 3195/4885CHRM5 3902/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | SIGMAR1 583/4885CHRM3 915/4885CHRM5 519/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | SIGMAR1 583/4885CHRM3 915/4885CHRM5 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.